Edesa Biotech Inc. reports FY research and development expenses of USD 3.7 million, up 27%

Reuters12-13

<a href="https://laohu8.com/S/EDSA">Edesa Biotech</a> Inc. reports FY research and development expenses of USD 3.7 million, up 27%

Edesa Biotech Inc. reported a net loss of USD 7.2 million, or USD 1.27 per common share, for the full year ended September 30, 2025. This compares to a net loss of USD 6.2 million, or USD 1.93 per common share, for the previous year. As of September 30, 2025, Edesa Biotech Inc. held cash and cash equivalents of USD 10.8 million and reported working capital of USD 10.4 million. General and administrative expenses for the period increased to USD 4.2 million, primarily due to higher noncash share-based compensation. Total other income for the year was USD 0.7 million, mainly reflecting a decrease in interest income. Subsequent to the fiscal year end, the company raised USD 3.4 million in net proceeds from the sale of common shares under an at-the-market offering program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9601061) on December 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591572681?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-13 05:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591572681","market":"us","top_or_hot":-1,"title":"Edesa Biotech Inc. reports FY research and development expenses of USD 3.7 million, up 27%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EDSA\">Edesa Biotech</a> Inc. reports FY research and development expenses of USD 3.7 million, up 27%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Edesa Biotech Inc. reported a net loss of USD 7.2 million, or USD 1.27 per common share, for the full year ended September 30, 2025. This compares to a net loss of USD 6.2 million, or USD 1.93 per common share, for the previous year. As of September 30, 2025, Edesa Biotech Inc. held cash and cash equivalents of USD 10.8 million and reported working capital of USD 10.4 million. General and administrative expenses for the period increased to USD 4.2 million, primarily due to higher noncash share-based compensation. Total other income for the year was USD 0.7 million, mainly reflecting a decrease in interest income. Subsequent to the fiscal year end, the company raised USD 3.4 million in net proceeds from the sale of common shares under an at-the-market offering program.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9601061) on December 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edesa Biotech Inc. reports FY research and development expenses of USD 3.7 million, up 27%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdesa Biotech Inc. reports FY research and development expenses of USD 3.7 million, up 27%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-13 05:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EDSA\">Edesa Biotech</a> Inc. reports FY research and development expenses of USD 3.7 million, up 27%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Edesa Biotech Inc. reported a net loss of USD 7.2 million, or USD 1.27 per common share, for the full year ended September 30, 2025. This compares to a net loss of USD 6.2 million, or USD 1.93 per common share, for the previous year. As of September 30, 2025, Edesa Biotech Inc. held cash and cash equivalents of USD 10.8 million and reported working capital of USD 10.4 million. General and administrative expenses for the period increased to USD 4.2 million, primarily due to higher noncash share-based compensation. Total other income for the year was USD 0.7 million, mainly reflecting a decrease in interest income. Subsequent to the fiscal year end, the company raised USD 3.4 million in net proceeds from the sale of common shares under an at-the-market offering program.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9601061) on December 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014005.SGD","symbol_name":"United Global Durable Equities Fund Acc SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL6phxf:1","article_id":"2591572681","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591572681","pubTimestamp":1765574431,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Edesa Biotech Inc. reported a net loss of USD 7.2 million, or USD 1.27 per common share, for the full year ended September 30, 2025. This compares to a net loss of USD 6.2 million, or USD 1.93 per common share, for the previous year. As of September 30, 2025, Edesa Biotech Inc. held cash and cash equivalents of USD 10.8 million and reported working capital of USD 10.4 million. General and administrative expenses for the period increased to USD 4.2 million, primarily due to higher noncash share-based compensation. Total other income for the year was USD 0.7 million, mainly reflecting a decrease in interest income. Subsequent to the fiscal year end, the company raised USD 3.4 million in net proceeds from the sale of common shares under an at-the-market offering program.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4139":"生物科技","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","EDSA":"Edesa Biotech"},"translate_title":"Edesa Biotech Inc.报告财年研发费用为370万美元，增长27%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EDSA":0.9,"NDAQ":0.9},"content_text":"Edesa Biotech Inc. reports FY research and development expenses of USD 3.7 million, up 27%\n    \n\n        Edesa Biotech Inc. reported a net loss of USD 7.2 million, or USD 1.27 per common share, for the full year ended September 30, 2025. This compares to a net loss of USD 6.2 million, or USD 1.93 per common share, for the previous year. As of September 30, 2025, Edesa Biotech Inc. held cash and cash equivalents of USD 10.8 million and reported working capital of USD 10.4 million. General and administrative expenses for the period increased to USD 4.2 million, primarily due to higher noncash share-based compensation. Total other income for the year was USD 0.7 million, mainly reflecting a decrease in interest income. Subsequent to the fiscal year end, the company raised USD 3.4 million in net proceeds from the sale of common shares under an at-the-market offering program.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9601061) on December 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591572681","isCrawlerRequest":true}